Pancreatic Cancer Research

ResearcherShandong UniversityActive in the last 2 years

Zhenhai Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4479-7205; OpenAlex author ID A5101788543. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. TWIST1 regulates HK2 ubiquitination degradation to promote pancreatic cancer invasion and metastasis. Last author DOI 10.1186/s12935-024-03583-z↗
  2. Knockdown of TGF-β in Pancreatic Cancer Helps Ameliorate Gemcitabine Resistance. Co-author DOI 10.31083/j.fbl2907269↗
  3. Corrigendum to "Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1" [Canc. Le… Co-author DOI 10.1016/j.canlet.2022.215739↗
  4. [Corrigendum] Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ijo.2020.5157↗
  5. TWIST1 transcriptionally regulates glycolytic genes to promote the Warburg metabolism in pancreatic cancer. Co-author DOI 10.1016/j.yexcr.2019.111713↗
  6. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis. Co-author DOI 10.1016/j.canlet.2016.11.006↗
  7. Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ijo.2017.4099↗
  8. HOXA10 promotes cell invasion and MMP-3 expression via TGFβ2-mediated activation of the p38 MAPK pathway in pancreatic cancer cells. Co-author DOI 10.1007/s10620-014-3033-6↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xinxing Wang · 5 shared papers, 2017–2025 · strength 0.84
  2. Guozhe Xian · 5 shared papers, 2017–2022 · strength 0.59
  3. Chengkun Qin · 5 shared papers, 2014–2022 · strength 0.53
  4. Zhiyi Wang · 3 shared papers, 2017–2021 · strength 0.33
  5. Zhongxue Su · 3 shared papers, 2014–2022 · strength 0.32
  6. Xianping Cui · 3 shared papers, 2014–2021 · strength 0.26
  7. Junlin Gao · 1 shared paper, 2024 · strength 0.23
  8. Xingsong Tian · 1 shared paper, 2014 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.